European regulators will clamp down on "pay-for-delay" deals in the pharmaceutical sector this month, fining Denmark's Lundbeck, India's Ranbaxy and seven other generic drug manufacturers for limiting access of cheaper products to the market.
Following an inquiry launched in 2009, the European Commission, the EU's anti-trust regulator, will impose a "significant" fine on Lundbeck and lesser fines on Germany's Merck KGaA and seven smaller drug firms when it announces the sanctions later this month, two officials said.
The fines underscore the determination of EU and US regulators to break agreements that involve brand name drug companies paying generic manufacturers not to deliver cheaper drugs to the market, a process that ultimately harms consumers.
European regulators have estimated that consumers are paying up to 20 per cent more for medicines in some cases.
The Commission can fine a company up to 10 per cent of its global revenue for breaching EU antitrust laws, which in Lundbeck's case would be up to euro 240